A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The purpose of this study is to find out whether talazoparib in combination with enzalutamide or talazoparib alone delays cancer progression in people with metastatic castration-resistant prostate cancer (mCRPC) who have homologous recombination repair (HRR) mutations and have previously received abiraterone acetate.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek 18 lat lub więcej
- •Chęć udziału w badaniu i zgodność z jego zasadami
- •Zdolność do połykania kapsułek i tabletek badania
- •Potwierdzony histologicznie rak gruczołowy prostaty
- •Mutacja w genach odpowiedzialnych za napraws DNA (BRCA1, BRCA2, ATM, CDK12 i inne)
- •Zaawansowany rak prostaty (przerzuty) potwierdzony badaniami obrazowymi
- •Gotowość do pozostania w badaniu pomimo wzrostu poziomu PSA, jeśli stan zdrowia się nie pogarsza
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- July 13, 2026
- Sex
- Male only
Therapies / drugs in trial
Locations (7)
City of Hope
Duarte, United States
Dana Farber Cancer Institute
Boston, United States
Masonic Cancer Center
Minneapolis, United States
Memorial Sloan Kettering Cancer Center
New York, United States
Abramson Cancer Center of the University of Pennsylvania, Hospital of the University of Pennsylvania
Philadelphia, United States
Fred Hutchinson Cancer Center
Seattle, United States
University of Wisconsin Carbone Cancer Center-Madison
Madison, United States
Trial contact
Sarah Wise
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 7/14/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.